NEW DRUGS IN THE TREATMENT OF CHRONIC HEPATITIS C
- Authors: Abdurakhmanov DT1, Abdurakhmanov D.T.1
-
Affiliations:
- Issue: No 15 (2010)
- Pages: 50-53
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278608
- ID: 278608
Cite item
Full Text
Abstract
The article discusses the prospects for the treatment of chronic hepatitis C (CHC) using a new class of drugs with direct antiviral action. The most promising combination is combination of protease or polymerase with pegylated interferon alpha and ribavirin; the results of phase II clinical studies show significantly increase of effectiveness of treatment of patients with CHC using such combinations. The article presents results of evaluation of efficacy of telaprevir, R7227 and R7128 in patients with CHC.
References
- McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection. N Engl J Med 2009;360:1827-38.
- Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. N Engl J Med 2009;360:1839-50.
- McHutchison JG, Manns MP, Muir A, et al. Telaprevir for Previously Treated Chronic HCV Infection. N Engl J Med 2010;362:1292-303.
- Forestier N, Zeuzem S, Larrey D, et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of results of a phase 1b multiple ascending dose study. Hepatology 2008;48:1847.
- Sarrazin C, Zeuzeum S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447-62.
- Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007;46:862-63.
- Gane EJ, Rodriguez-Torres M, Nelson DE, et al. Sustained virologic response (SVR) following RG7128 1500mg bid/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior nonresponders. J Hepatology 2010;52(1):16.
- Gane EJ, Roberts SK, Stedman C, et al. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. J Hepatol 2009;50(1):380.
Supplementary files
